

Bayer appoints a new President

11 June 2014 | News | By BioSpectrum Bureau



Singapore: Bayer pharmaceuticals announced changes in the top management, declaring Mr Dieter Weinand as the president of Bayer HealthCare Pharmaceuticals, effective from August 1, 2014.

Mr Weinand, aged 53 years would also be joining the Executive Committee of Bayer HealthCare. He previously served as the President of Global Commercialization for Otsuka Pharmaceutical Development and Commercialization, a \$13 billion revenue healthcare business.

"We welcome Mr Dieter Weinand to our management team. Based on his extensive commercial experience in the pharmaceutical industry, Mr Weinand will drive the growth of our pharmaceutical business further and maximize the value of our product portfolio," said Mr Olivier Brandicourt, CEO of Bayer HealthCare.

Mr Dieter Weinand has more than 25 years of experience in various commercial, operative and strategic executive roles in the pharmaceutical industry.

His expertise has been built on experiences gained from across different markets such as Asia-Pacific, Europe, Middle East, Africa, Latin America and the USA. He has also served giant pharma companies including Pfizer and Bristol-Myers Squibb and has marketed a variety of products in different therapeutic areas such as cardiology, oncology, pulmonology, dermatology, immunology and inflammation.